Construction method and application of KIF5C mutation animal model
By constructing a KIF5C mutant gene knock-in animal model using CRISPR/Cas9 technology, the problems of inconsistent evaluation standards and poor reproducibility of existing autism models have been solved, providing an efficient and stable animal model for research on the pathogenesis of autism and drug development.
Patent Information
- Application Number
- CN202410901027.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-12
AI Technical Summary
Existing animal models for autism have inconsistent evaluation criteria, poor reproducibility, and complex procedures, and lack effective genetic modification models, making it difficult to meet the needs of autism research and drug development.
A KIF5C mutant gene knock-in animal model was constructed using CRISPR/Cas9 technology. Specific sgRNA and homologous vectors containing the mutation site were designed and introduced into fertilized eggs to breed the KIF5C mutant gene knock-in animal model. Combined with genotype identification and screening, an efficient and stable animal model was constructed.
The constructed KIF5C mutant gene knock-in animal model is highly efficient, controllable, and easy to reproduce. It can stably simulate the neurodevelopmental disorders and behavioral characteristics of autism, supporting research on the pathogenesis of autism and drug development.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004930474140000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a method for constructing a KIF5C mutation animal model and an application thereof. Background Art
[0002] Autism Spectrum Disorder (ASD), also known as autism, is a developmental disorder of the brain and nervous system with social interaction disorders, language communication disorders, narrow interests and repetitive stereotyped behaviors as the core clinical manifestations. The incidence rate is about 1%. The disease seriously affects the neuropsychiatric health of the children themselves and is a social problem that urgently needs attention. A successful autism model is the key to studying the pathogenesis and treatment of autism.
[0003] Currently, there are few animal models that can effectively reflect the cause of the disease. There are many problems such as inconsistent evaluation criteria for model success, poor repeatability, and complex operations. Autism is an extremely complex developmental disorder that is closely related to multiple factors. It is currently believed that the heritability of autism can be as high as 70%-90%, so the establishment of a genetically modified autism model has broad application prospects. Summary of the invention
[0004] The present invention aims to provide a method and application of constructing a KIF5C mutant gene knock-in animal model based on CRISPR / Cas9 technology, so as to provide an effective experimental animal model for the mechanism research of autism, as well as drug development and efficacy evaluation.
[0005] The purpose of the first aspect of the present invention is to provide a kit for constructing a KIF5C mutant gene knock-in animal model.
[0006] The purpose of the second aspect of the present invention is to provide the use of the kit of the first aspect of the present invention in constructing a KIF5C mutant gene knock-in animal model.
[0007] The purpose of the third aspect of the present invention is to provide a method for constructing a KIF5C mutant gene knock-in animal model based on CRISPR / Cas9 technology.
[0008] The purpose of the fourth aspect of the present invention is to provide an application of the KIF5C mutant gene knock-in animal model constructed by the method described in the third aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.
[0009] The technical solution adopted by the present invention is:
[0010] In a first aspect of the present invention, a kit for constructing a KIF5C mutant gene knock-in animal model is provided, comprising sgRNA1 and / or sgRNA2, wherein the sequence of the sgRNA1 is shown in SEQ ID NO.1; the sequence of the sgRNA2 is shown in SEQ ID NO.2.
[0011] In some embodiments of the present invention, the kit further comprises Cas9 mRNA and / or a homologous vector containing a mutation site, and the mutation site is c.2344G>A.
[0012] In some embodiments of the present invention, the nucleotide sequence of the homologous vector containing the mutation site is shown as SEQ ID NO:3.
[0013] In some embodiments of the present invention, the kit further comprises an amplification primer and / or a sequencing primer.
[0014] In some embodiments of the present invention, the sequences of the amplification primers are shown in SEQ ID NO:4 and SEQ ID NO:5.
[0015] In some embodiments of the present invention, the sequencing primer sequence is shown as SEQ ID NO.6.
[0016] The second aspect of the present invention provides use of the kit of the first aspect of the present invention in constructing a KIF5C mutant gene knock-in animal model.
[0017] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.
[0018] In some preferred embodiments of the present invention, the animal model is a rat.
[0019] The third aspect of the present invention provides a method for constructing a KIF5C mutant gene knock-in animal model, which comprises constructing the model using the kit according to the first aspect of the present invention.
[0020] In some embodiments of the present invention, the method comprises: introducing a mixture of the Cas9 mRNA, the homologous vector containing the mutation site and the sgRNA into the fertilized egg of the model animal, obtaining a viable fertilized egg, transplanting it into a surrogate mother, breeding, obtaining offspring and performing genotype identification and screening to obtain a KIF5C mutant gene knock-in animal model.
[0021] In some embodiments of the present invention, the mass ratio of the Cas9 mRNA, the homologous vector and the sgRNA is 1:0.5-1.5:0.5-1.5.
[0022] In some embodiments of the present invention, the mass ratio of sgRNA1 to sgRNA2 is 1:0.5-1.5.
[0023] In some embodiments of the present invention, in the mixture, the final concentrations of the Cas9 mRNA, the homologous vector containing the mutation site, and the sgRNA are 100-300 ng / μL, 100-300 ng / μL, and 100-300 ng / μL, respectively.
[0024] In some embodiments of the present invention, the method of introducing comprises injection.
[0025] In some embodiments of the present invention, the genotype identification and screening includes taking tail blood from offspring animals, amplifying and sequencing by PCR.
[0026] In some preferred embodiments of the present invention, the primers used in the PCR amplification include a primer pair of Rat KIF5C-F and Rat KIF5C-R, the base sequence of the primer Rat KIF5C-F is shown in SEQ ID NO:4, and the base sequence of the primer RatKIF5C-R is shown in SEQ ID NO:5.
[0027] In some preferred embodiments of the present invention, the base sequence of the sequencing primer used in the sequencing process is shown in SEQ ID NO:6.
[0028] In some embodiments of the present invention, the viable fertilized eggs are transplanted into a surrogate mother and the offspring obtained are named F0 generation animal model; the positive F0 generation animal model obtained by genotype identification and screening is mated with the wild type to obtain an F1 generation animal model; the F1 generation heterozygous animal model obtained by genotype identification and screening is hybridized to obtain an F2 generation animal model, and the positive F2 generation animal model obtained by genotype identification and screening is obtained, that is, the KIF5C mutant gene knock-in animal model.
[0029] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.
[0030] In some preferred embodiments of the present invention, the animal model is a rat.
[0031] The fourth aspect of the present invention provides the use of the KIF5C mutant gene knock-in animal model constructed by the construction method described in the third aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.
[0032] The beneficial effects of the present invention are:
[0033] The present invention first discovered that the KIF5C gene mutated in the genome of children with autism, and the mutation site was c.2344G>A. To this end, based on the mutation site, the present invention provides a sgRNA specifically targeting the KIF5C mutant gene and a kit containing the sgRNA, through which a KIF5C mutant gene (c.2344G>A) knock-in animal model can be constructed based on CRISPR / Cas9 gene editing technology; the animal model has high knock-in efficiency, high controllability, good repeatability, and is easy to breed and raise, which makes up for the shortcomings of existing animal models, and is more stable and more in line with clinical characteristics, which is helpful for the study of the pathogenic mechanism of autism and the development of autism drugs; it has good prospects for medical clinical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The present invention uses CRISPR / Cas9 to construct a KIF5C mutant gene knock-in rat autism animal model.
[0035] Figure 2 This is the PCR result identification and sequencing diagram of the F0 generation #82 KIF5C gene mutation knock-in rat. The upper picture is the wild type, and the lower picture is the F0 generation #82 mouse.
[0036] Figure 3 This is a graph showing the changes in brain weight in rats with KIF5C mutant gene knock-in.
[0037] Figure 4 The KIF5C mutant gene knock-in rat model has social disorder behavior. Figure 4 A is a rat sociability test in the three-box experiment. Left: thermal imaging of the interaction between the experimental rat and the stranger rat 1 (S1) and the empty box (E); right: quantification of the interaction time between the experimental rat and the stranger rat 1 (S1) and the empty box (E). Figure 4 B is the frequency of social interaction of the model mice, including the number of times the experimental mice sniffed, followed, and pushed the unfamiliar mice.
[0038] Figure 5 The KIF5C mutant gene knock-in rat model has repetitive stereotypic behaviors. Figure 5 A shows the grooming situation of the model mice when they were active in an open field. Figure 5 B shows the bead burial situation of model mice.
[0039] Figure 6 Changes in brain tissue and neurons in rats with KIF5C mutant gene knock-in. Figure 6 A is the immunohistochemical expression of KIF5C protein in the brain of model mice. Figure 6 B is the expression level of KIF5C protein in the brain of model mice. Figure 6 C is the immunofluorescence image of neurons in the prefrontal cortex of the model mouse brain. DETAILED DESCRIPTION
[0040] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0041] Unless otherwise specified, the materials and reagents used in this example were obtained from commercial sources.
[0042] Example 1
[0043] In clinical work, the inventors of the present invention found a child with autism. The proband's Child Autism Parent Rating Scale (ABC) and Child Autism Rating Scale (CARS) scores were 56 and 35 points respectively, confirming that the child was autistic. Further sequencing analysis of its genomic DNA revealed that its KIF5C gene had a mutation, c.2344G>A. Based on the above, the inventors constructed a KIF5C mutant gene knock-in rat autism animal model based on the child's mutation site c.2344G>A using CRISPR / Cas9 technology;
[0044] The specific steps include:
[0045] (1) Cas9 / gRNA target design
[0046] The nucleotide sequence of the rat KIF5C gene (NM_001107730.1) was downloaded from the NCBI database and homologous comparison was performed. According to the mutation site c.2344G>A in the child, the mutation site c.2344G>A was determined on the homologous sequence of the rat. The sgRNA sequences, including sgRNA1 and sgRNA2, were designed based on this site sequence;
[0047] Among them, the nucleotide sequence of sgRNA1 is 5'-GGACTCCCTCAGCGAGGAGCTGG-3' (SEQ ID NO: 1), and the nucleotide sequence of sgRNA2 is 5'-TTTACCTTGGGCCCGGAGCTTGG-3' (SEQ ID NO: 2).
[0048] (2) Construction of homologous recombination vector (Donor vector)
[0049] The homologous recombination vector Donor vector carries a mutation site, and its vector sequence is 5'-TACATGCAGAACATGGAACAGAAGAGGCGGCAGCTGGAAGAGTCGCAGGACT CCCTCAGCAAGGAGCTGGCAAAGCTCCGGGCCCAAGGTAAATATTGACTCCTTTG CAGGTGTCAAACACTT-3' (SEQ ID NO: 3).
[0050] (3) sgRNA in vitro transcription: sgRNA was designed according to the target sequence, and an in vitro transcription vector sgRNA was constructed. After the sgRNA was expanded and cultured, the plasmid was extracted and digested with DraⅠ and then recovered by gel. The recovered product was used as a template, and in vitro transcription was completed with T7 RNA polymerase. The product was purified by gel recovery and finally concentrated to 200ng / μl by ethanol precipitation. It was evenly mixed with Cas9mRNA and Donor vector at a final concentration ratio of 200ng / μL:200ng / μL:200ng / μL, where the mass ratio of sgRNA1 and sgRNA2 was 1:1.
[0051] (4) Preparation of fertilized eggs: Select 3-4 week old SD female mice and inject them with pregnant mare serum (PMSG) and human chorionic gonadotropin (hCG) respectively, with an interval of 46-48 hours between the two. After the injection of HCG, mate the female mice with adult fertile male mice to fertilize them. The next day, euthanize the female mice, collect the fertilized eggs from the fallopian tubes, and place them in a constant temperature incubator of 37°C and 5% CO2 for later use.
[0052] (5) Pronuclear microinjection: prepare microinjection needles and fixing needles; add the prepared mRNA injection solution to the microinjection needle; select fertilized eggs with normal morphology and place them in an injection dish. Under an inverted microscope with a magnification of 200 to 400 times, inject the exogenous gene injection solution into the nucleus of the fertilized egg by microinjection; transfer the injected fertilized eggs to M16 culture medium and place them in a constant temperature 37°C 5% CO2 incubator for 0.5 to 1 hour before transplantation.
[0053] (6) Preparation of surrogate mice and embryo transplantation
[0054] Prepare pseudo-pregnant female mice: select fertile female mice of appropriate age and mate with male mice that have been sterilized after vasectomy to stimulate a series of pregnancy changes in the female mice to obtain pseudo-pregnant female mice, which will serve as surrogate mice after the genetically modified fertilized eggs; transplant the fertilized eggs that have been injected with foreign genes into the fallopian tubes of surrogate female mice on the day of thrombus formation; after the transplantation, place the surrogate female mice in a clean cage and keep them warm until they wake up and then return them to the cage for breeding; after a successful fallopian tube transplantation, the female mice will generally give birth 19-20 days after the operation; one week after the mice are born, their claws can be clipped and numbered, and PCR identification can be performed at the same time; three weeks after the mice are born, they can be raised independently in separate cages.
[0055] (7) Identification of F0 mice
[0056] Collect tissues (tail or toe tissues) from 1- to 2-week-old young mice; lyse the tissues and extract genomes;
[0057] PCR amplification and electrophoresis detection are performed using specific primers for the target gene to screen out offspring with the integration of the exogenous gene; mice with integration are called founder mice and can be passaged and established, and protein expression levels can be identified if necessary.
[0058] Among them, the specific primer sequences used for genotype identification of KIF5C mutant gene knock-in rats include RatKIF5C-F (5'-GCTGTACAGCATCTGGAAGCAAGC-3', SEQ ID NO: 4) and Rat KIF5C-R (5'-GGGATTCAGCAAGGTGACCAATC-3', SEQ ID NO: 5), the sequencing primer is sequence-F (5'-CGTTCCACGGCGAGGTCTCT-3', SEQ ID NO: 6), the PCR amplification system is shown in Table 1, and the amplification program is shown in Table 2.
[0059] Filter results such as Figure 2 As shown, after amplification, the wild-type and mutant sequences were both 649 bp, the wild-type sequence was shown in SEQ ID NO: 7, the KIF5C mutant sequence was shown in SEQ ID NO: 8, and the positive F0 rat obtained by screening was numbered #82.
[0060] Table 1 PCR amplification system
[0061] Reaction components Volume (μL) <![CDATA[2X Premix TaqddH2O]]> 10 <![CDATA[ddH2O]]> 8 Primer F (Rat KIF5C-F) 0.5 Primer R (Rat KIF5C-R) 0.5 DNA Template 1 Total 20
[0062] Table 2 PCR amplification program
[0063]
[0064]
[0065] SEQ ID NO:7(WT PCR product):649bp
[0066] Gctgtacagcatctggaagcaagctgcagagtacatggaagaaacagagaactccctgggtcctcagctctgagtcccaggcaaaggagaaaacgagccgttccacggcgaggtctctaacttgtcctgtcctattggacagctccagagaagcccgcacagccagatgctgggtactcacctttccttccggtctgttttcttactcacagcatgaagccaagatcaagtctctgacagactacatgcagaacatggaacagaagaggcggcagctggaagagtcgcaggactccctcagcgaggagctggccaagctccgggcccaaggtaaatattgactcctttgcaggtgtcaaacacttggctgaagccagcctctagctggctgagttctgatgtttggttttgttcaggaactacaacataactgaaagctacccctgtgtgtctgctgcttcccagcttccctctgtccacccagctgacttggccagcatcctccttccaacccagttgacctcttgctctgcaaagctcgtcccttaggctttcagatttgtctctggtgctgctcatgtctcttaggactgccttggagcggggtctcactgccgtcttctctggattggtcaccttgctgaatccc;
[0067] SEQ ID NO:8(Mutant PCR product):649bp
[0068] gctgtacagcatctggaagcaagctgcagagtacatggaagaaacagagaactccctgggtcctcagctctgagtcccaggcaaaggagaaaacgagccgttccacggcgaggtctctaacttgtcctgtcctattggacagctccagagaagcc cgcacagccagatgctgggtactcacctttccttccggtctgttttcttactcacagcatgaagccaagatcaagtctctgacagactacatgcagaacatggaacagaagaggcggcagctggaagagtcgcaggactccctcagcAaggagctg gca aagctccgggcccaaggtaaatattgactcctttgcaggtgtcaaacacttggctgaagccagcctctagctggctgagttctgatgtttggtttttgttcaggaactacaacataactgaaagctacccctgtgtgtctgctgcttcccagcttccctctgtccacccagctgacttggccagcatcctccttccaacccagttgacctcttgctctgcaaagctcgtcccttaggctttcagatttgtctctggtgctgctcatgtctcttaggactgccttggagcggggtctcactgccgtcttctctggattggtcaccttgctgaatccc, among which, the uppercase font represents the mutation site c.2344G>A, and the underlined one represents the silent mutation gcc>gca.
[0069] (8) The positive F0 generation rats grown to 8 weeks old were mated with wild-type rats of the opposite sex to obtain F1 generation rats, and tail blood was collected for PCR amplification and identification (the detailed process is the same as step (3)) to obtain F1 generation heterozygous rats. The F1 generation heterozygous rats grown to 8 weeks old were further crossed to obtain F2 generation rats, and tail blood was collected for PCR amplification and identification (same as above) to obtain positive F2 generation homozygous rats, namely KIF5C mutant gene knock-in rats (KIF5C mutant rats), and the KIF5C mutant gene knock-in rat autism animal model was constructed ( Figure 1 ).
[0070] Effect Example
[0071] 1. Brain weight
[0072] The brains of the KIF5C wild-type (WT) and KIF5C mutant (HO) rats of the same littermate constructed in Example 1 were taken out and weighed.
[0073] The results showed that the brain weight of KIF5C mutant rats was not significantly different from that of wild-type rats ( Figure 3 ).
[0074] 2. Social interaction test
[0075] One week before the experiment, the experimental rats were pre-pacified for 10 minutes each day to eliminate the influence of anxiety and fear caused by the experimental operator's grasping and smell on the experimental results. On the day of the experiment, the experimental rats were first placed in the three boxes and allowed to freely explore the familiar box environment for 10 minutes; then a strange wild-type rat Stranger1 (S1) of the same age and gender was placed in the cage of box A. At this time, cage B was empty, and the activities of the experimental rats in the three boxes were tracked and recorded for 10 minutes.
[0076] The results showed that HO rats spent significantly less time in the chamber with the unfamiliar rat, suggesting that HO rats had reduced social preference ( Figure 4 A).
[0077] Social interaction experiments are also one of the means of detecting social disorders. By observing the free interaction of mice, their social ability can be evaluated. The test rats and unfamiliar rats are placed in an open field box at the same time, and the time and frequency of the test rats' activities such as sniffing, following, pushing, and attacking the unfamiliar rats are monitored.
[0078] Figure 4 B shows that HO rats have a significantly reduced preference for animals of the same species. The above results indicate that the social preference of KIF5C mutant rats is significantly affected.
[0079] 3. Analysis of stereotyped behaviors of bead burying and grooming
[0080] Grooming stereotyped behavior analysis: Place the test rat in the center of the open field box and allow it to explore freely for 30 minutes. Monitor the number or duration of grooming behaviors in the open field box to assess the repetitive stereotyped behaviors of the test rats and whether hyperactivity and anxiety increase. Self-grooming behavior is the self-cleaning behavior of animals under physiological conditions. Excessive repetitive grooming behavior under pathological conditions can be used as an indicator for evaluating repetitive stereotyped behaviors.
[0081] The results showed that the frequency and duration of grooming in KIF5C gene mutant rats increased significantly ( Figure 5 A).
[0082] Marble Burying Test Analysis: The marble burying test (MBT) is a useful model of obsessive-compulsive, anxiety-related, and repetitive behaviors. It is used to evaluate phenotypes associated with anxiety and obsessive-compulsive disorder in rat models. Rats are placed in a cage containing marbles. If more than two-thirds of the glass bead is covered by the bedding, it is considered to be buried by the mouse.
[0083] The experimental results showed that the number of beads buried by KIF5C gene mutant rats was significantly higher than that of wild-type rats ( Figure 5 B), the above results reflect that KIF5C gene mutant rats have repetitive stereotyped behaviors.
[0084] 4. Brain tissue and neuron detection
[0085] The KIF5C mutant gene knock-in rats constructed in Example 1 were euthanized, and the brains were removed for immunohistochemical staining and WB detection.
[0086] The results showed that compared with wild-type rats, the expression of KIF5C protein in the brain tissue of the KIF5C mutant gene knock-in rats constructed in Example 1 was reduced ( Figure 6 A, B).
[0087] Primary cortical neurons of young rats within 24 hours of birth were cultured in vitro. Seven days later, the neurons were marked with axon-specific marker protein Tau1 and dendrite-specific marker protein Map2. The results of cell immunofluorescence staining showed that the axons of primary cortical neurons of KIF5C mutant rats were shorter and the dendritic branches were reduced compared with those of wild-type rats ( Figure 6 C).
[0088] It can be seen from the above results that the KIF5C mutant gene knock-in rat autism animal model constructed by the method of Example 1 can successfully simulate human autism disease, with a phenotype of neurodevelopmental disorder, and its homozygous mutations show social disorders and repetitive stereotyped behaviors. When conducting pathogenic mechanism research, it was found that the KIF5C protein level in the brain tissue of the model rats decreased, the neuronal axons were shortened, and the dendritic branches were reduced.
[0089] In summary, this model can be used to study the pathogenic mechanism of autism caused by the KIF5C gene and may have great application value in the development of drugs for the treatment of autism.
[0090] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A kit for constructing a KIF5C mutant gene knock-in animal model, comprising sgRNA1 and / or sgRNA2, wherein the sequence of the sgRNA1 is shown in SEQ ID NO.1; the sequence of the sgRNA2 is shown in SEQ ID NO.
2.
2. The kit according to claim 1, characterized in that The kit also includes Cas9 mRNA and / or a homologous vector containing a mutation site, and the mutation site is c.2344G>A.
3. The kit according to claim 2, characterized in that The nucleotide sequence of the homologous vector is shown in SEQ ID NO:
3.
4. The kit according to claim 1, characterized in that The kit further comprises detection primers, which include amplification primers and / or sequencing primers; preferably, the sequences of the amplification primers are as shown in SEQ ID NO.4 and SEQ ID NO.5; preferably, the sequence of the sequencing primers is as shown in SEQ ID NO.
6.
5. Use of the kit according to any one of claims 1 to 4 in constructing a KIF5C mutant gene knock-in animal model.
6. The use according to claim 5, characterized in that: The animal model is one of a mouse, a rat, and a monkey; preferably, the animal model is a rat.
7. A method for knocking in a KIF5C mutant gene into an animal model, characterized in that: The method comprises constructing the kit using any one of claims 1 to 4.
8. The method according to claim 7, characterized in that The method comprises: introducing a mixture of the Cas9 mRNA, homologous vector and sgRNA into a fertilized egg of a model animal, obtaining a viable fertilized egg, transplanting the egg into a surrogate mother, breeding, obtaining offspring and performing genotype identification and screening, thereby obtaining a KIF5C mutant gene knock-in animal model.
9. The method according to claim 8, characterized in that The mass ratio of the Cas9 mRNA, homologous vector and sgRNA is 1:0.5-1.5:0.5-1.5; preferably, the mass ratio of the sgRNA1 and sgRNA2 is 1:0.5-1.
5.
10. Use of the KIF5C mutant gene knock-in animal model constructed by the construction method according to any one of claims 7 to 9 in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.
